Evidence mapPaperPMID 42311404Full record

ReviewFrontiers in pharmacology2026

Research progress on potential high-risk drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining.

Houci Yang, Junjun Xu, Jiali Zhang, Xiaoyu Zhang, Chenghui Jin, Haibin Dai, Mingdong Yang

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Houci YangDepartment of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Junjun XuDepartment of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jiali ZhangDepartment of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiaoyu ZhangDepartment of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Chenghui JinDepartment of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Haibin DaiDepartment of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Mingdong YangDepartment of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare yet life-threatening severe cutaneous adverse drug reactions (SCARs), characterized by high mortality and substantial morbidity risks. Identifying potential high-risk drugs associated with SJS/TEN is crucial for guiding clinical preventive interventions, enabling early detection, and enhancing risk management. With the rapid advancement of data science, adverse drug reaction (ADR) database mining has emerged as a powerful tool for systematically investigating the drug-SJS/TEN association, effectively overcoming the limitations of traditional case reports and small-sample studies regarding data scale and conclusion generalizability. This review summarizes recent advances in identifying potential high-risk drugs for SJS/TEN based on ADR database mining, with all included studies retrieved from peer-reviewed journals and strictly focused on SJS/TEN. We classify and discuss the major potential high-risk drug categories, including antibiotics, antiepileptics, allopurinol, nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), immune checkpoint inhibitors (ICIs), novel antiandrogens, carbonic anhydrase inhibitors, antivirals, and others. We also summarize their associated genetic susceptibilities, median onset times, and underlying mechanisms. These findings provide valuable references for enhancing medication safety and mitigating severe adverse drug reactions in clinical practice.

Indexed as

adverse drug reaction (ADR)data miningpharmacovigilanceStevens-Johnson syndrome (SJS)the FDA adverse event reporting system (FAERS)time to onset (TTO)toxic epidermal necrolysis (TEN)

Identifiers

PMID42311404
PMCPMC13269370

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.